<DOC>
	<DOCNO>NCT02002585</DOCNO>
	<brief_summary>Kidney protection study ( KPS 1 ) prospective randomize clinical study compare use renal denervation ( RDN ) optimal medical therapy subject chronic kidney disease stage 3-4 resistant arterial hypertension optimal medical therapy alone . Renal denervation modern endovascular method use treat resistant hypertension . The method extend group patient , sympathetic tone increase beyond resistant hypertension . Because character disease , hypothesize renal denervation reduce prevent progressive deterioration kidney function patient population . The aim clinical study show renal denervation protective effect progression chronic renal insufficiency .</brief_summary>
	<brief_title>Renal Protection Using Sympathetic Denervation Patients With Chronic Kidney Disease</brief_title>
	<detailed_description>Background : patient chronic renal insufficiency ideal group renal denervation ( RDN ) , increase sympathetic tone . This increase lead sodium retention , reduction perfusion kidney excessive activation renin angiotensin aldosterone system . The activation sympathetic system significantly contribute progression chronic renal insufficiency . The consequence hyperactivity sympathetic system affect selective renal sympathectomy . RDN demonstrably reduce retention sodium , reduce production renin significantly reduce renal vascular resistance . Furthermore , RDN reduce microalbuminuria renal podocyte damage experimental model . RDN also improve renal function model acute Glomerulonephritis . In patient resistant hypertension preserve renal function , also show renal denervation improve renal resistant index significantly decrease microalbuminuria . The procedure find safe study renal denervation associate deterioration renal function . Several experimental data exist effectiveness RDN chronic renal insufficiency . In model acute renal failure mouse ( endotoxemia model ) , show RDN protective effect renal function . The decline glomerular filtration endotoxemia significantly low group treat RDN compare control group . In addition , renal flow acute renal failure RDN improve . In model heart failure mouse , show RDN combination olmesartan reduce albuminuria damage podocytes also reduce level renal norepinephrine , angiotensinogen , angiotensin II , level oxidative stress . Very data effect RDN renal function human also publish . Renal damage hypertensive subject find RDN Symplicity system 3 year post procedure . Mahfoud coworkers show subject treat RDN low blood pressure renal resistive index time stabilize renal function . The number patient microalbuminuria macroalbuminuria decrease significantly one year RDN . RDN also positive effect albuminuria proteinuria patient preserve renal function . The first study perform patient chronic kidney disease ( CKD stage 3-4 ) resistant hypertension do Hering et coworkers . In study , 15 patient average eGFR 31ml/min/1 , 73m2 underwent RDN . The author able show RDN effectively lower blood pressure associate deterioration renal function . RDN positive effect hemoglobin concentration , proteinuria BNP level . Moreover , augmentation index peripheral artery also improve RDN . This work show multiple effect RDN beyond reduction blood pressure . We , therefore think patient chronic kidney disease good candidate RDN . However , mention study relatively short term follow ( 6 month one year ) comparative arm . Aim study : propose trial aim show RDN contribute improve control blood pressure patient resistant hypertension also protective effect kidney function subject chronic kidney disease . Our trial comparative arm last 3 year . Planned intervention : The two strategy go compare optimal medical therapy optimal medical therapy renal denervation .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Signed informed consent Age 1880 year Chronic renal insufficiency CKD 34 nephrologist ( eGFR ( MDRD ) ≤ 45 ml/min/1.73 m2 ) Arterial hypertension treat : systolic BP ≥ 140 mmHg + least 3 antihypertensive drug Including diuretic systolic BP ≥ 135 mmHg + 3 antihypertensive Including diuretic + diabetes mellitus type 2. systolic BP ≥ 130 mmHg 24 hr ABPM + 3 antihypertensive drug Including diuretic • Renal artery diameter ≥ 4 mm accord renal angiography ( documented quantitative renal angiography ) , renal artery length least 20mm Secondary hypertension White coat hypertension abnormalities renal angiogram disqualifying RDN Life expectancy &lt; 1 year Type 1 . Diabetes mellitus Significant stenotic valvular heart disease Acute coronary syndrome unstable angina past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Renal protection</keyword>
	<keyword>Renal sympathetic denervation</keyword>
</DOC>